Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04167670 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Vonoprazan Compared to Lansoprazole in Participants With Helicobacter Pylori Infection
A Phase 3 study, sponsored by Phathom Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,046
- Enrollment target
NCT04167670: Completed Phase 3 study, sponsored by Phathom Pharmaceuticals.
NCT04167670 is a Phase 3 study that has completed, run by Phathom Pharmaceuticals. The registered enrollment target is 1,046 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (35% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04167670, a Phase 3 study, has completed, sponsored by Phathom Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,046 participants
- Enrollment target
Study Summary
To compare the efficacy of Helicobacter pylori (HP) eradication with vonoprazan dual and triple therapy regimens versus lansoprazole triple therapy regimen in participants with HP infection, excluding participants who had a clarithromycin or amoxicillin resistant strain of HP at baseline.
Primary Outcome
H pylori eradication was determined by the \^13C-UBT test.
Interventions
- DRUG Amoxicillin
- DRUG Vonoprazan
- DRUG Clarithromycin
- DRUG Lansoprazole
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,046 participants |
| Start Date | 2019-12-10 |
| Est. Completion | 2021-03-18 |
| Phase | Phase 3 |
What the finished NCT04167670 record still lists
NCT04167670 is an interventional study that assigns participants to a tested intervention. Its 1,046 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (35% higher).
The record links to 0 conditions, and to 4 interventions - of which Amoxicillin is the first listed.
NCT04167670 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04167670 about?
NCT04167670 is a clinical study titled "Efficacy and Safety of Vonoprazan Compared to Lansoprazole in Participants With Helicobacter Pylori Infection". To compare the efficacy of Helicobacter pylori (HP) eradication with vonoprazan dual and triple therapy regimens versus lansoprazole triple therapy regimen in participants with HP infection, excluding participants who had a clarithromycin or amoxicillin resistant strain of HP at baseline.
What is the current status of trial NCT04167670?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,046 participants. The study started on 2019-12-10. Estimated completion is 2021-03-18.
What interventions are being tested in trial NCT04167670?
The interventions under investigation include: Amoxicillin (DRUG), Vonoprazan (DRUG), Clarithromycin (DRUG), Lansoprazole (DRUG).
Who is sponsoring clinical trial NCT04167670?
This trial is sponsored by Phathom Pharmaceuticals, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04167670's enrollment target sits among peer trials
1,046 283rd of 2000 higher than 1,717 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06717347 · 1,046 participants · Phase 3
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
- NCT04505618 · 1,050 participants · NA
Optical Coherence Tomography Angiography in Subjects With Retinal Vascular Disease
- NCT04511806 · 1,050 participants
Childhood Cancer Predisposition Study (CCPS)
- NCT05028972 · 1,050 participants · NA
Hearing Impairment, Strategies and Outcomes in VA Emergency Departments
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI